Comparison of melanoma types between the United States and Japan. 1)SSM, superficial spreading melanoma; NM, nodular melanoma; LMM, lentigo maligna melanoma; ALM, acral lentiginous melanoma
Acral melanomas (AM) is a distinct subtype of melanoma affecting the palms, soles and nail apparatuses. It is mostly identical to acral lentiginous melanoma according to Clark’s classification (Clark et al., 1986), but it may also include nodular melanoma and superficial spreading melanoma that developed on glabrous skin and nail apparatus (Curtin et al., 2005). While AM is the least frequent subtype of cutaneous melanoma overall in Caucasians, it is the most prevalent type of melanoma in people of color. Prognosis of AM is generally poor, which may be in part due to delay in diagnosis (Bradford et al., 2009).
The distinct histological and phenotypic characteristics suggest that AM might differ biologically from other types of cutaneous melanomas. Recent molecular genetic studies characterized AM as a unique type of melanoma showing higher frequency of chromosomal aberrations, especially focused amplifications of particular chromosome regions (Bastian et al., 2000; Curtin et al., 2005). Furthermore, recent discovery of frequent mutation or amplification of
Although AM accounts for 5% of all melanomas in the United States (Markovic et al., 2007)(Table 1), it is a predominant form of melanoma in individuals with darker skin (ie, Blacks, Asians and Hispanics) (Cormier et al., 2006). The proportion of AM among all melanoma subtypes is greatest in blacks followed by Asians/Pacific islanders and Hispanic whites (Bradford et al., 2009). The nation-wide survey in Japan shows that AM accounts for 41% of all melanomas (Ishihara et al., 2008)(Table 1), the rate being almost the same in Chinese (Chi et al., 2011). However, the absolute incidence of AM in darker-skinned individuals is similar to that in whites (Stevens et al., 1990; Bradford et al., 2009), who have a much higher incidence of melanoma overall due to the strong susceptibility to sunlight (Cormier et al., 2006). Thus, carcinogens other than ultraviolet light (UVL) equally affecting all ethnic groups or endogenous mutagenesis may play a role in the development of AM. Trauma may have a role in AM development, since 13% to 25% of patients with AM reported prelesional trauma, such as puncture wounds, friction blisters and stone bruises (Coleman et al., 1980; Phan et al., 2006). The mean age at diagnosis of AM is 62.8 years, compared with 58.5 years for cutaneous melanoma overall. Incidence of AM significantly increases with each year of advancing age, which is seen across the different racial groups (Bradford et al., 2009).
|Type of Melanoma1)||United States|
(Markovic et al., 2007)
(Ishihara et al., 2008)
Although acral volar skin and nail beds constitutes only a few % of skin surface, the fact that nearly half of cutaneous melanomas arise on these anatomical sites in darker-skinned individuals indicates that these are predilection sites of melanomas not causally related to UVL exposure. The melanocyte density in palmoplantar skin is five times lower than that found in nonpalmoplantar sites. Furthermore, the growth and differentiation of palmoplantar melanocytes are suppressed by dickkopf 1 (DKK1) secreted from dermal fibroblasts through the down-regulation of microphthalmia-associated transcription factor (MITF) and beta-catenin (Yamaguchi et al., 2004). The reason why such growth-suppressed melanocytes in palmoplantar skin are more susceptible to melanoma development is currently unknown.
3. Clinical features
Clinically, AMs on palms and soles begin with irregularly pigmented macular lesions. The soles of the feet are most commonly involved. Morphological characteristics of early AM lesions include variable shades of brown from tan to black color, irregular and asymmetric shape often accompanied by notching at the periphery, and over 7mm in diameter (Saida, 1989) (Fig. 1a).
Dermoscopic observations of these early lesions show band-like pigmentation on ridges of the skin markings, designated as a “parallel ridge pattern”(Fig. 2a). This is in sharp contrast to the dermoscopic patterns in acral melanocytic nevi, which show parallel linear pigmentation along the sulci of the skin markings, designated as a “parallel furrow pattern”(Fig. 2b) and its variants “lattice-like pattern“ (Fig. 2c) and “fibrillar pattern”(Fig. 2d) (Oguchi et al., 1998; Miyazaki et al., 2005). The sensitivity and specificity of the parallel ridge pattern in diagnosing early AM is 86% and 99%, respectively (Saida et al., 2004). A simple three-step algorism effectively discriminating early AM from acral melanocytic nevi has been proposed (Fig. 3) (Saida et al., 2011). This algorism classifies acquired pigmented lesions on acral volar skin by the dermoscopic findings and the maximal diameter, and recommends three management options including “no need to follow-up”, “periodic follow-up”, and “excision of the lesion for histopathological evaluation”.
In contrast to the palmoplantar melanoma, nail apparatus melanoma more often affects fingers than the toes. The digits most commonly affected are the thumb followed by the great toe. If the AM is situated in the nail matrix, a longitudinal pigmented band of the nail plate is the earliest sign (Fig. 4a). As melanocytic nevi of the nail matrix also typically accompany longitudinal melanonychia, identifying early nail matrix melanoma is challenging. Dermoscopy again provides useful information for this differentiation. The suspicious dermoscopic features of early nail matrix melanoma are irregular lines on a brown background, pigmentation of the cuticle (micro-Hutchingson’s sign), a wide pigmented band, and triangular pigmentation on the nail plate (Fig. 4b) (Koga et al., 2011).
The tumorigenic vertical growth phase of palmoplantar melanoma is characterized by the development of a nodule often associated with ulceration (Fig. 1b). The development of a subungal tumor and the destruction of the nail plate are observed in the vertical growth phase of nail apparatus melanoma.
Histopathology of the earliest lesions of palmoplantar melanoma shows proliferation of solitary arranged slightly atypical melanocytes mainly detected in the crista profunda intermedia, the epidermal rete ridge underlying the ridges of the skin markings (Ishihara et al., 2006). In early nail apparatus melanoma, slightly atypical melanocytes proliferate in the epidermis of nail matrix. Eventually, large atypical melanocytes, frequently with prominent pigmented dendrites, proliferate as single cells in the basal layer of the hyperplastic epidermis while some tumor cells can be found in the upper layer of the epidermis. Nesting of melanocytes is not prominent, and tends to occur at the tips of the rete ridges. Brisk lichenoid lymphocytic infiltrate that may obscure the dermal-epidermal junction is common. In the vertical growth phase, atypical tumor cells are often spindle-shaped. Desmoplastic change is not uncommon (Clark et al., 1986).
5. Molecular genetics
There exists clinical heterogeneity in cutaneous melanoma with different susceptibility to UVL, which may be explained by differences in somatic genetic changes. Recent molecular genetic investigations have revealed that melanomas from intermittently sun-exposed skin, most of which are located on trunk and extremities, show frequent mutations in either
|Acral melanomas||Melanomas from intermittently sun-exposed skin||Reference|
|23% mutated||59% mutated||(Curtin et al., 2005)|
|10% mutated||22% mutated||(Curtin et al., 2005)|
|(Curtin et al., 2006)|
|44% amplified||5% amplified||(Sauter et al., 2002)|
|19% amplified||3% amplifieda||(Chernoff et al., 2009)|
Cyclin D1 positively regulates the activity of cyclin dependent kinases, leading to phosphorylation of retinoblastoma protein promoting entry into mitosis, and acts as an oncogene (reviewed in (Tashiro et al., 2007)). Interestingly, while gene amplifications are usually found in association with disease progression in other cancers,
While mutations of the
GAB2 is a scaffolding protein that mediates interactions with various signaling pathways including RAS-RAF-ERK and PI3K-AKT signaling, and is a critical molecule for melanoma progression (Horst et al., 2009). A recent study found
6. Molecular targeted therapy
Clinically, dramatic response to imatinib therapy has been observed in several sporadic cases with metastatic acral and mucosal melanomas with
Three phase-II trials of imatinib in unselected metastatic melanomas were mostly disappointing, and highlighted the importance of proper patient selection (Ugurel et al., 2005; Wyman et al., 2006; Kim et al., 2008). There are currently three ongoing clinical trials prospectively testing imatinib in selected patients with melanoma showing
|Imatinib||2||00470470||Mutation or amplification|
|Imatinib||2||00424515||Mutation or amplification|
|Imatinib||2||00881049||Mutation or amplification|
|Imatinib and temozolomide||1/2||00667953||Mutation|
|Nilotinib||2||00788775||Mutation or amplification|
|Nilotinib and dacarbazine||3||01028222||Mutation|
|Sunitinib||2||00631618||Mutation or amplification|
|Dasatinib and dacarbazine||1/2||00597038||None|
Nilotinib is a second-generation tyrosine kinase inhibitor of KIT, PDGFR and BCR-ABL. Nilotinib is potent as imatinib against mutant
It is now clear that melanoma arises from multiple pathways, with initiating and promoting factors differing for each. Melanomas on intermittently sun-exposed skin preferentially affect Caucasians who have an inherently high propensity for melanocyte proliferation characterized by high nevus counts (Whiteman et al., 2003). Exposure to intense bursts of UVL radiation, especially in childhood, is the major risk factor. This type of melanomas may arise from pre-existing melanocytic nevus, and the mutation of the
The author’s works were supported by the Grants-in-Aid for Cancer Research from the Ministry of Health, Labor, and Welfare of Japan (15–10 and 21S-7), Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (17659336 and 20591318), and a Management Expenses Grant from the Japanease Government to the National Cancer Center (21S-7(6)). I thank many colleagues who worked with me at the Department of Dermatology, Shinshu University, Japan, for their contributions to the studies of acral melanoma.
Ashida A. Takata M. Murata H. Kido K. Saida T. 2009Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. 124 4 862 868, 1097-0215
Bastian B. C. 2003Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer. 22 20 3081 3086, 0950-9232
Bastian B. C. Kashani-Sabet M. Hamm H. Godfrey T. Moore D. 2Godfrey, T., Moore, D. H., 2nd, Brocker, E. B., LeBoit, P. E. & Pinkel, D. (2000). Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. 60 7 1968 1973, 0008-5472
Bradford P. T. Goldstein A. M. Mc Master M. L. Tucker M. A. 2009Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. 145 4 427 434, 1538-3652
Carvajal R. D. Chapman P. B. Wolchok J. D. Cane L. Teitcher J. B. Lutzky J. 2009A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. , Orlando, May-June, 2009.
Chernoff K. A. Bordone L. Horst B. Simon K. Twadell W. Lee K. Cohen J. A. Wang S. Silvers D. N. Brunner G. Celebi J. T. 2009GAB2 amplifications refine molecular classification of melanoma. 15 13 4288 4291, 1078-0432
Chi Z. Li S. Sheng X. Si L. Cui C. Han M. Guo J. 2011Clinical presentation, histology, and prognosis of malignent melanoma in ethnic Chinese: A study of 522 consecutive cases., 11 85 94, 1471-2407
Clark W. H. Jr Elder D. E. Van Horn M. 1986The biologic forms of malignant melanoma. 17 5 443 450, 0046-8177
Coleman W. 33rd, Loria, P. R., Reed, R. J. & Krementz, E. T. (1980). Acral lentiginous melanoma. 116 7 773 776, 0000-3987X
Cormier J. N. Y. Ding M. Lee J. E. Mansfield P. F. Gershenwald J. E. Ross M. I. Du X. L. 2006Ethnic differences among patients with cutaneous melanoma. 166 17 1907 1914, 0003-9926
Curtin J. A. Busam K. Pinkel D. Bastian B. C. 2006Somatic activation of KIT in distinct subtypes of melanoma. 24 26 4340 4346, 1527-7755
Curtin J. A. Fridlyand J. Kageshita T. Patel H. N. Busam K. J. Kutzner H. Cho K. H. Aiba S. Brocker E. B. Le Boit P. E. Pinkel D. Bastian B. C. 2005Distinct sets of genetic alterations in melanoma. 353 20 2135 2147, 1533-4406
Fisher D. E. Barnhill R. Hodi F. S. Herlyn M. Merlino G. Medrano E. Bastian B. Landi M. T. Sosman J. 2010Melanoma from bench to bedside: meeting report from the 6th international melanoma congress. 23 1 14 26, 0175-5148X
Garrido M. C. Bastian B. C. 2010KIT as a therapeutic target in melanoma. 130 1 20 27, 1523-1747
Guo J. Si L. Kong Y. Xu X. w. Flaherty K. T. Corless C. L. Zhu Y. Y. Li L. Li H. F. 2010A phase II study of imatinib for advanced melanoma patients with KIT aberrations. Chicago, June, 2010.
Hodi F. S. Friedlander P. Corless C. L. Heinrich M. C. Mac Rae. S. Kruse A. Jagannathan J. Van den Abbeele. A. D. Velazquez E. F. Demetri G. D. Fisher D. E. 2008Major response to imatinib mesylate in KIT-mutated melanoma. 26 12 2046 2051, 1527-7755
Hofmann U. B. Kauczok-Vetter C. S. Houben R. Becker J. C. 2009Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. 15 1 324 329, 1078-0432
Horst B. Gruvberger-Saal S. K. Hopkins B. D. Bordone L. Yang Y. Chernoff K. A. Uzoma I. Schwipper V. Liebau J. Nowak N. J. Brunner G. Owens D. Rimm D. L. Parsons R. Celebi J. T. 2009Gab2-mediated signaling promotes melanoma metastasis. 174 4 1524 1533, 1525-2191
Ishihara K. Saida T. Otsuka F. Yamazaki N. 2008Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. 13 1 33 41, 1341-9625
Ishihara Y. Saida T. Miyazaki A. Koga H. Taniguchi A. Tsuchida T. Toyama M. Ohara K. 2006Early acral melanoma in situ: correlation between the parallel ridge pattern on dermoscopy and microscopic features. 28 1 21 27, 0193-1091
Jiang X. Zhou J. Yuen N. K. Corless C. L. Heinrich M. C. Fletcher J. A. Demetri G. D. Widlund H. R. Fisher D. E. Hodi F. S. 2008Imatinib targeting of KIT-mutant oncoprotein in melanoma. 14 23 7726 7732, 1078-0432
Kim K. B. Eton O. Davis D. W. Frazier M. L. Mc Conkey D. J. Diwan A. H. Papadopoulos N. E. Bedikian A. Y. Camacho L. H. Ross M. I. Cormier J. N. Gershenwald J. E. Lee J. E. Mansfield P. F. Billings L. A. Ng C. S. Charnsangavej C. Bar-Eli M. Johnson M. M. Murgo A. J. Prieto V. G. 2008Phase II trial of imatinib mesylate in patients with metastatic melanoma. 99 5 734 740, 1532-1827
Kluger H. M. Dudek A. Z. Mc Cann C. Ritacco J. Southard N. Jilaveanu L. B. Molinaro A. Sznol M. 2010A phase 2 trial of dasatinib in advanced melanoma. 117 10 2202 2208 0000-8543X
Koga H. Saida T. Uhara H. 2011Key point in dermoscopic differentiation between early nail apparatus melanoma and benign longitudinal melanonychia. 38 1 45 52, 1346-8138
Lutzky J. Bauer J. Bastian B. C. 2008Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. 21 4 492 493, 1755-1471
Markovic S. N. Erickson L. A. Rao R. D. Weenig R. H. Pockaj B. A. Bardia A. Vachon C. M. Schild S. E. Mc Williams R. R. Hand J. L. Laman S. D. Kottschade L. A. Maples W. J. Pittelkow M. R. Pulido J. S. Cameron J. D. Creagan E. T. 2007Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. 82 3 364 380, 0025-6196
Michaloglou C. Vredeveld L. C. Mooi W. J. Peeper D. S. 2008BRAF(E600) in benign and malignant human tumours. 27 7 877 895, 1476-5594
Miyazaki A. Saida T. Koga H. Oguchi S. Suzuki T. Tsuchida T. 2005Anatomical and histopathological correlates of the dermoscopic patterns seen in melanocytic nevi on the sole: a retrospective study. 53 2 230 236, 1097-6787
Murata H. Ashida A. Takata M. Yamaura M. Bastian B. C. Saida T. 2007Establishment of a novel melanoma cell line SMYM-PRGP showing cytogenetic and biological characteristics of the radial growth phase of acral melanomas. 98 7 958 963, 1347-9032
North J. P. Kageshita T. Pinkel D. Leboit P. E. Bastian B. C. 2008Distribution and Significance of Occult Intraepidermal Tumor Cells Surrounding Primary Melanoma. 128 8 2024 2030, 1523-1747
Oguchi S. Saida T. Koganehira Y. Ohkubo S. Ishihara Y. Kawachi S. 1998Characteristic epiluminescent microscopic features of early malignant melanoma on glabrous skin. A videomicroscopic analysis. 134 5 563 568, 0000-3987X
Phan A. Touzet S. Dalle S. Ronger-Savle S. Balme B. Thomas L. 2006Acral lentiginous melanoma: a clinicoprognostic study of 126 cases. 155 3 561 569, 0007-0963
Romano E. Schwartz G. K. Chapman P. B. Wolchock J. D. Carvajal R. D. 2011Treatment implications of the emerging molecular classification system for melanoma. Vol. No. pp. 1474-5488 1474 5488
Saida T. 1989Malignant melanoma in situ on the sole of the foot. Its clinical and histopathologic characteristics. 11 2 124 130, 0193-1091
Saida T. Koga H. Uhara H. 2011Key points in dermoscopic differentiation between early acral melanoma and acral nevus. 38 1 25 34, 1346-8138
Saida T. Miyazaki A. Oguchi S. Ishihara Y. Yamazaki Y. Murase S. Yoshikawa S. Tsuchida T. Kawabata Y. Tamaki K. 2004Significance of dermoscopic patterns in detecting malignant melanoma on acral volar skin: results of a multicenter study in Japan. 140 10 1233 1238, 0000-3987X
Sauter E. R. Yeo U. C. von Stemm. A. Zhu W. Litwin S. Tichansky D. S. Pistritto G. Nesbit M. Pinkel D. Herlyn M. Bastian B. C. 2002Cyclin D1 is a candidate oncogene in cutaneous melanoma. 62 11 3200 3206, 0008-5472
Stevens N. G. Liff J. M. Weiss N. S. 1990Plantar melanoma: is the incidence of melanoma of the sole of the foot really higher in blacks than whites? 45 4 691 693, 0020-7136
Takata M. Murata H. Saida T. 2010Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma. 23 1 64 71, 0175-5148X
Tashiro E. Tsuchiya A. Imoto M. 2007Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. 98 5 629 635. ISSN
Terheyden P. Houben R. Pajouh P. Thorns C. Zillikens D. Becker J. C. 2010Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene. 130 1 314 316, 1523-1747
Ugurel S. Hildenbrand R. Zimpfer A. La Rosee P. Paschka P. Sucker A. Keikavoussi P. Becker J. C. Rittgen W. Hochhaus A. Schadendorf D. 2005Lack of clinical efficacy of imatinib in metastatic melanoma. 92 8 1398 1405, 0007-0920
Whiteman D. C. Watt P. Purdie D. M. Hughes M. C. Hayward N. K. Green A. C. 2003Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. 95 11 806 812, 1460-2105
Woodman S. E. Davies M. A. 2010Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. 80 5 568 574, 1873-2968
Woodman S. E. Trent J. C. Stemke-Hale K. Lazar A. J. Pricl S. Pavan G. M. Fermeglia M. Gopal Y. N. Yang D. Podoloff D. A. Ivan D. Kim K. B. Papadopoulos N. Hwu P. Mills G. B. Davies M. A. 2009Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. 8 8 2079 2085, 1538-8514
Wyman K. Atkins M. B. Prieto V. Eton O. Mc Dermott D. F. Hubbard F. Byrnes C. Sanders K. Sosman J. A. 2006Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. 106 9 2005 2011, 0000-8543X
Yamaguchi Y. Itami S. Watabe H. Yasumoto K. Abdel-Malek Z. A. Kubo T. Rouzaud F. Tanemura A. Yoshikawa K. Hearing V. J. 2004Mesenchymal-epithelial interactions in the skin: increased expression of dickkopf1 by palmoplantar fibroblasts inhibits melanocyte growth and differentiation. 165 2 275 285, 0021-9525
Yamaura M. Takata M. Miyazaki A. Saida T. 2005Specific dermoscopy patterns and amplifications of the cyclin D1 gene to define histopathologically unrecognizable early lesions of acral melanoma in situ. 141 11 1413 1418, 0000-3987X